carmustine has been researched along with isoxazoles in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Evans, RG; Kimler, BF; Liu, C; Morantz, RA | 1 |
| Beattie, BJ; Blasberg, RG; Malkin, MG; Thiessen, B; Vlassenko, AG | 1 |
| Cherrington, JM; Kabbinavar, F; Mann, E; Schwartz, DP; Shawver, LK; Slamon, DJ; Strawn, LM | 1 |
| Cho, E; Choi, K; Khosla, C; Omary, B; Piper, JL; Rich, KM; Siegel, M; Strnad, P; Yuan, L | 1 |
| Choi, K; Jackson, EN; Khosla, C; Miller, CR; Piwnica-Worms, D; Rich, KM; Siegel, M; Yuan, L | 1 |
5 other study(ies) available for carmustine and isoxazoles
| Article | Year |
|---|---|
Intracerebral chemotherapy in the 9L rat brain tumor model.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Benzoquinones; Bleomycin; Brain Neoplasms; Carmustine; Cisplatin; Injections, Intralesional; Injections, Intraperitoneal; Isoxazoles; Male; Neoplasm Transplantation; Rats; Rats, Inbred F344 | 1992 |
Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biological Transport, Active; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Disease Progression; Disease-Free Survival; Energy Metabolism; Female; Fluorodeoxyglucose F18; Gadolinium DTPA; Glioblastoma; Glucose; Humans; Isoxazoles; Leflunomide; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Platelet-Derived Growth Factor; Prognosis; Signal Transduction; Supratentorial Neoplasms; Tomography, Emission-Computed; Treatment Outcome | 2000 |
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Division; Cell Survival; Cisplatin; Etoposide; Glioblastoma; Head and Neck Neoplasms; Humans; Isoxazoles; Leflunomide; Lung Neoplasms; Mice; Mice, Nude; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Carmustine; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Glioblastoma; GTP-Binding Proteins; Intestine, Small; Isoxazoles; Mice; Mice, Inbred C3H; Microscopy, Confocal; Protein Glutamine gamma Glutamyltransferase 2; Structure-Activity Relationship; Transglutaminases | 2005 |
Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Enzyme Inhibitors; Extracellular Matrix; Female; Fibronectins; Fluorescent Antibody Technique; Glioblastoma; GTP-Binding Proteins; Humans; Isoxazoles; Mice; Mice, Inbred BALB C; Protein Glutamine gamma Glutamyltransferase 2; RNA, Small Interfering; Survival Rate; Transglutaminases; Tumor Cells, Cultured | 2007 |